Eli Lilly launched programs to expand employer coverage and alternative access pathways for its GLP‑1 obesity drugs, including an employer‑focused service and a platform to ease workplace reimbursement. Lilly said the initiatives are designed to address stalled payer coverage and open new channels for patients with employer‑sponsored insurance. Company executives and industry observers characterized the moves as tactical responses to slow insurer uptake and regulatory uncertainty around obesity therapeutics. For employers, the programs offer subscription‑style procurement options and administrative models intended to reduce cost friction. The effort signals that major manufacturers will increasingly use nontraditional commercial pathways—alongside payer negotiations—to grow patient access.